Relieves heartburn associated with acid indigestion and sour stomach.
Prevents heartburn associated with acid indigestion and sour stomach
brought on by certain foods and beverages.
Directions: Adults and children 12 years and over:
To relieve symptoms, swallow 1 tablet with a glass of water
To prevent symptoms, swallow 1 tablet with a glass of water 30 to 60
minutes before eating food or drinking beverages that cause heartburn
can be used up to twice daily (up to 2 tablets in 24 hours)
children under 12 years: ask a doctor
store at 20°-25°C (68°-77°F)
avoid excessive heat or humidity
Ingredients: Active Ingredients: each tablet: Ranitidine 75mg (as
Ranitidine Hydrochloride 84mg) (acid reducer)
Inactive Ingredients: Hypromellose, Magnesium Stearate,
Microcrystalline Cellulose, Synthetic Red Iron Oxide, Titanium Dioxide,
Warnings: Allergy Alert: Do not use if you are allergic to
ranitidine or other acid reducers
Do not use:
if you have trouble swallowing
with other acid reducers
Stop use and ask a doctor if:
stomach pain continues
you need to take this product for more than 14 days
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. In case of overdose, get medical help or
contact a poison control center right away.
Ranitidine HCl - Zantac is a histamine H2-receptor antagonist. Chemically it is
The empirical formula is C13H22N4O3SˇHCl, representing a molecular weight
Ranitidine HCl is a white to pale yellow, granular substance that is
soluble in water. It has a slightly bitter taste and sulfurlike odor.
Each Zantac 150 tablet for oral administration contains 168 mg of
ranitidine HCl equivalent to 150 mg of ranitidine. Each tablet also
contains the inactive ingredients FD&C yellow No. 6 aluminum lake,
hydroxypropyl methylcellulose, magnesium stearate, microcrystalline
cellulose, titanium dioxide, triacetin, and yellow iron oxide.
Each Zantac 300 tablet for oral administration contains 336 mg of
ranitidine HCl equivalent to 300 mg of ranitidine. Each tablet also
contains the inactive ingredients croscarmellose sodium, D&C yellow No. 10
aluminum lake, hydroxypropyl methylcellulose, magnesium stearate,
microcrystalline cellulose, titanium dioxide, and triacetin.
Zantac 150 geldose capsules and Zantac 300 geldose capsules for oral
administration are soft gelatin capsules containing 168 mg of ranitidine
HCl equivalent to 150 mg of ranitidine and 336 mg of ranitidine HCl
equivalent to 300 mg of ranitidine, respectively, in a nonaqueous matrix
of synthetic coconut oil and synthetic triglycerides. The soft gelatin
capsule shell contains gelatin, sorbitol special (sorbitol and sorbitol
anhydrides), glycerin, purified water, titanium dioxide, FD&C yellow No.
6, FD&C blue No. 1, and FD&C red No. 40. The capsule shell may also
contain mineral oil and soybean lecithin. The capsules are printed with
Zantac 150 EFFERdose tablets and Zantac 150 EFFERdose granules for oral
administration are effervescent formulations of ranitidine that must be
dissolved in water before use. Each individual tablet or the contents of a
packet contain 168 mg of ranitidine HCl equivalent to 150 mg of ranitidine
and the following inactive ingredients: aspartame, monosodium citrate
anhydrous, povidone, and sodium bicarbonate. Each tablet also contains
sodium benzoate. The total sodium content of each tablet is 183.12 mg
(7.96 mEq) per 150 mg of ranitidine, and the total sodium content of each
packet of granules is 173.54 mg (7.55 mEq) per 150 mg of ranitidine.
Each 1 ml of Zantac syrup contains 16.8 mg of ranitidine HCl equivalent to
15 mg of ranitidine. Zantac syrup also contains the inactive ingredients
alcohol (7.5%), butylparaben, dibasic sodium phosphate, hydroxypropyl
methylcellulose, peppermint flavor, monobasic potassium phosphate,
propylparaben, purified water, saccharin sodium, sodium chloride, and
Injection, Injection Premixed, and Injection Pharmacy Bulk PackagežNot for
Ranitidine HCl Injection is a clear, colorless to yellow, nonpyrogenic
liquid. The yellow color of the liquid tends to intensify without
adversely affecting potency. The pH of the injection solution is 6.7 to
Sterile Injection for Intramuscular or Intravenous Administration or
Injection Pharmacy Bulk Package: Each 1 ml of aqueous solution contains
ranitidine 25 mg (as the hydrochloride); phenol 5 mg as preservative; and
0.96 mg of monobasic potassium phosphate and 2.4 mg of dibasic sodium
phosphate as buffers.
Injection Pharmacy Bulk PackagežNot for Direct Infusion:
A pharmacy bulk
package is a container of a sterile preparation for parenteral use that
contains many single doses. The contents are intended for use in a
pharmacy admixture program and are restricted to the preparation of
admixtures for intravenous (IV) infusion.
Sterile, Premixed Solution for Intravenous Administration in Single-Dose,
Flexible Plastic Containers: Each 50 ml contains ranitidine HCl equivalent
to 50 mg of ranitidine, sodium chloride 225 mg, and citric acid 15 mg and
dibasic sodium phosphate 90 mg as buffers in water for injection. It
contains no preservatives. The osmolarity of this solution is 180 mOsm/l
(approx.), and the pH is 6.7 to 7.3.
The flexible plastic container is fabricated from a specially formulated,
nonplasticized, thermoplastic co-polyester (CR3). Water can permeate from
inside the container into the overwrap but not in amounts sufficient to
affect the solution significantly. Solutions inside the plastic container
also can leach out certain of the chemical components in very small
amounts before the expiration period is attained. However, the safety of
the plastic has been confirmed by tests in animals according to USP
biological standards for plastic containers.